JP2019521990A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521990A5
JP2019521990A5 JP2018565845A JP2018565845A JP2019521990A5 JP 2019521990 A5 JP2019521990 A5 JP 2019521990A5 JP 2018565845 A JP2018565845 A JP 2018565845A JP 2018565845 A JP2018565845 A JP 2018565845A JP 2019521990 A5 JP2019521990 A5 JP 2019521990A5
Authority
JP
Japan
Prior art keywords
composition
use according
item
subject
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018565845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521990A (ja
JP6814822B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/038003 external-priority patent/WO2017218974A2/en
Publication of JP2019521990A publication Critical patent/JP2019521990A/ja
Publication of JP2019521990A5 publication Critical patent/JP2019521990A5/ja
Application granted granted Critical
Publication of JP6814822B2 publication Critical patent/JP6814822B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018565845A 2016-06-16 2017-06-16 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 Active JP6814822B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351234P 2016-06-16 2016-06-16
US62/351,234 2016-06-16
PCT/US2017/038003 WO2017218974A2 (en) 2016-06-16 2017-06-16 Treatment of amd using aav2 variant with aflibercept

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020155475A Division JP2020203941A (ja) 2016-06-16 2020-09-16 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置

Publications (3)

Publication Number Publication Date
JP2019521990A JP2019521990A (ja) 2019-08-08
JP2019521990A5 true JP2019521990A5 (https=) 2020-07-02
JP6814822B2 JP6814822B2 (ja) 2021-01-20

Family

ID=60663653

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018565845A Active JP6814822B2 (ja) 2016-06-16 2017-06-16 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2020155475A Withdrawn JP2020203941A (ja) 2016-06-16 2020-09-16 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2022113865A Pending JP2022137244A (ja) 2016-06-16 2022-07-15 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2024095160A Pending JP2024113193A (ja) 2016-06-16 2024-06-12 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2025152535A Pending JP2025186377A (ja) 2016-06-16 2025-09-12 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020155475A Withdrawn JP2020203941A (ja) 2016-06-16 2020-09-16 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2022113865A Pending JP2022137244A (ja) 2016-06-16 2022-07-15 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2024095160A Pending JP2024113193A (ja) 2016-06-16 2024-06-12 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP2025152535A Pending JP2025186377A (ja) 2016-06-16 2025-09-12 アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置

Country Status (25)

Country Link
US (2) US20190151409A1 (https=)
EP (3) EP3795181B1 (https=)
JP (5) JP6814822B2 (https=)
KR (2) KR102218265B1 (https=)
CN (2) CN117531025A (https=)
AU (3) AU2017286673B2 (https=)
BR (1) BR112018076124A2 (https=)
CA (1) CA3027737A1 (https=)
CY (1) CY1123697T1 (https=)
DK (2) DK3471780T3 (https=)
ES (2) ES2840059T3 (https=)
FI (1) FI3795181T3 (https=)
HR (2) HRP20251248T1 (https=)
HU (1) HUE051953T2 (https=)
IL (3) IL279919B2 (https=)
LT (2) LT3471780T (https=)
MX (2) MX391779B (https=)
PL (1) PL3795181T3 (https=)
PT (2) PT3471780T (https=)
RS (2) RS61311B1 (https=)
SG (1) SG11201811232XA (https=)
SI (2) SI3795181T1 (https=)
SM (2) SMT202500400T1 (https=)
WO (1) WO2017218974A2 (https=)
ZA (1) ZA201808538B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102537394B1 (ko) 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
DK3471780T3 (da) * 2016-06-16 2020-11-23 Adverum Biotechnologies Inc Behandling af amd med aav2-variant med aflibercept
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
CN110546257B (zh) 2017-03-17 2024-03-01 阿德夫拉姆生物技术股份有限公司 用于增强基因表达的组合物和方法
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
DK3717636T5 (da) * 2017-11-27 2024-08-26 4D Molecular Therapeutics Inc Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese
MX2020006435A (es) 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
WO2019198084A1 (en) * 2018-04-12 2019-10-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-aging compositions and methods of use
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
WO2020180951A1 (en) * 2019-03-04 2020-09-10 Adverum Biotechnologies, Inc. Sequential intravitreal administration of aav gene therapy to contralateral eyes
KR20220012231A (ko) * 2019-04-24 2022-02-03 리젠엑스바이오 인크. 완전-인간 번역 후 변형된 항체 치료제
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
FI4027983T3 (fi) * 2019-09-11 2026-02-03 Adverum Biotechnologies Inc Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla
AU2019465527A1 (en) * 2019-09-11 2022-03-10 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using AAV2 variants encoding aflibercept
US11400039B2 (en) 2020-01-16 2022-08-02 James W. Hill Changing eye color by gene transduction
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires
CN113952473A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
JP7842082B2 (ja) * 2020-07-21 2026-04-07 エフティージェン コーポレーション 眼疾患を処置するための組成物および方法
CN113952474A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CN113817775B (zh) * 2020-08-25 2023-02-17 南京吉迈生物技术有限公司 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
BR112023003548A2 (pt) * 2020-09-03 2023-04-04 Univ Massachusetts Vírus adenoassociado para liberação de kh902 (conbercept) e usos do mesmo
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
JP2021049374A (ja) * 2020-12-09 2021-04-01 株式会社三洋物産 遊技機
JP2024515459A (ja) * 2021-04-27 2024-04-10 アドヴェラム バイオテクノロジーズ， インコーポレイテッド アフリベルセプトをコードするａａｖ２バリアントを使用する眼疾患の治療方法
CN118660913A (zh) 2022-02-21 2024-09-17 上海瑞宏迪医药有限公司 Vegf结合分子及其医药用途
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025040166A1 (zh) 2023-08-23 2025-02-27 上海瑞宏迪医药有限公司 药物组合物及其用途
WO2025072688A2 (en) * 2023-09-27 2025-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells
WO2025073297A1 (zh) * 2023-10-06 2025-04-10 甘李药业股份有限公司 表达抗vegf融合蛋白的aav病毒载体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171334T1 (hr) * 2011-04-22 2017-11-17 The Regents Of The University Of California Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
HUE046134T2 (hu) * 2012-05-07 2020-02-28 Allergan Inc Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US20150111275A1 (en) * 2012-06-11 2015-04-23 Daniel V. Palanker Optical regulation of gene expression in the retina
AU2014286996A1 (en) * 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
WO2015058048A1 (en) * 2013-10-18 2015-04-23 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
DK3471780T3 (da) * 2016-06-16 2020-11-23 Adverum Biotechnologies Inc Behandling af amd med aav2-variant med aflibercept

Similar Documents

Publication Publication Date Title
JP2019521990A5 (https=)
JP2019521989A5 (https=)
HRP20201842T1 (hr) Liječenje amd korištenjem aav2 varijante s afliberceptom
HRP20220612T1 (hr) Sastavi i metode za smanjenje očne neovaskularizacije
JP2018520646A5 (https=)
Barnett et al. Complications of retinopathy of prematurity treatment
CN115554418B (zh) 一种重组腺相关病毒载体的药物组合物及其用途
CN108368165A (zh) 用于治疗颅内出血相关症状的方法和组合物
JP2018517773A (ja) ＩｇＧＦｃドメインを有する融合タンパク質の安定な液状製剤
Pan et al. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice
JP2018527941A5 (https=)
KR20180135913A (ko) 살아있는 약독화된 알파바이러스 구조체 그리고 그 방법 및 용도
TW202143998A (zh) 一種治療亨廷頓病的方法和藥物
US11000577B2 (en) Compositions and methods for treating neonatal biliary atresia
JP2020510648A5 (https=)
JP2018509154A5 (https=)
JP2023515916A (ja) 神経損傷及び関連障害を治療するための方法
CN117180455A (zh) 腺相关病毒药物组合物及其用途
Aziz et al. Review of gene therapy clinical trials for retinal diseases
JP7616697B2 (ja) ウイルス性肺炎を治療する方法及び薬剤
US20180000892A1 (en) Methods and pharmaceutical compositions for the treatment of ischemic conditions
JP2023525257A (ja) 脊髄性筋萎縮症を治療する方法及び薬剤
CN119909180A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
CN118831152A (zh) 导管素抗菌肽在缺血性脑卒中药物中的应用
NZ749897B2 (en) Treatment of amd using aav2 variant with aflibercept